Last updated: April 24, 2026
Who manufactures imipenem and cilastatin APIs?
Imipenem and cilastatin are typically supplied as:
- Imipenem (API)
- Cilastatin (API)
- Or the combination API (same-formulation producers that supply fixed-dose combination intermediates and final API)
The supplier set for the fixed-dose product (imipenem/cilastatin) is concentrated in a small number of API houses that support the global injectable market. The most common procurement structure is either:
1) Direct API supply from established global API manufacturers, or
2) CMO-manufactured API for branded and authorized generics, using a supplier’s controlled process and DMF/ASMF filings.
Which companies are consistently present in imipenem/cilastatin supply chains?
Below are major, recurring suppliers and supply-chain participants that support imipenem/cilastatin commercialization through API manufacturing, intermediation, and contract manufacturing. (A “recurring supplier” here means it appears across multiple sourcing networks used by global generics and branded supply.)
Global API and CMO suppliers (injectables)
- Sandoz (injectable antibiotics portfolio; supplies for global markets via internal and partner manufacturing)
- Teva (injectables and API supply chains)
- Mylan / Viatris (generics and injectable API supply)
- Dr. Reddy’s Laboratories (injectable generics supply chain)
- Accord BioPharma / Accord Healthcare (injectable manufacturing and sourcing network)
- Aurobindo Pharma (API and injectables supply)
- Sun Pharma (injectable generics and sourcing network)
- Lupin (injectable generics supply)
- Cipla (injectable generics and sourcing network)
- Sagent / Ascend-related networks (US-focused injectable supply chains)
- Fresenius Kabi (injectable medicines; sourcing and manufacturing network)
Dedicated API manufacturers and chemical intermediate houses (typical for this chemistry)
Imipenem/cilastatin manufacturing usually requires specialized beta-lactam capabilities, high-purity intermediates, and strict GMP controls. Procurement commonly pulls from:
- Beta-lactam specialist API manufacturers
- Cilastatin intermediate suppliers
- Imipenem core intermediate suppliers
- Fixed-dose API packagers and sterile fill-finish partners (when scope includes finished drug product)
Because “supplier” can mean different contract endpoints (API-only vs finished drug product), the most defensible buying approach is to anchor sourcing on DMF/ASMF-backed API and GMP sterile production where applicable.
What do buyers typically request from suppliers for imipenem/cilastatin?
For procurement and regulatory readiness, standard request packs cover:
API quality and regulatory documentation
- DMF/ASMF reference and letter-of-access (US) or equivalent dossier access (EU/other)
- GMP compliance evidence for relevant sites
- CoA specs (API assay, water content, related substances, particle size where applicable)
- Residual solvents statements
- Stability data and assigned retest period
- Change control history (process, site transfers, impurity profile updates)
Chemistry and compatibility controls (fixed-dose injectable)
- Cilastatin compatibility with imipenem solution conditions
- Impurity profile controls for the beta-lactam core and for cilastatin-related byproducts
- Controlled handling of moisture sensitivity and degradation pathways during API processing and bridging studies (where required)
What supplier categories exist for the drug’s manufacturing pipeline?
Procurement usually breaks into four layers:
- Imipenem API manufacturer
- Cilastatin API manufacturer
- Combination API producer (or API house that manufactures the co-formulated bulk)
- Sterile drug product manufacturer (when the buyer needs finished vials/infusion bottles)
Each layer has different qualification needs:
- API qualification focuses on assay, impurities, stability, and regulatory file access
- Sterile qualification focuses on aseptic process validation, endotoxin/sterility assurance, and container closure system
How do contract manufacturing and sourcing typically work?
Most suppliers operate one of these models:
Model A: API house to finished drug product
- Buyer sources bulk drug substance
- Buyer contracts sterile fill-finish and packaging under its own labeling authorization
Model B: Integrated API + drug product supply
- Supplier provides API and finished sterile product
- Buyer takes a lower coordination burden but pays for integration
Model C: License-holder and authorized generic framework
- Supplier is the API provider to a license-holder that owns finished product commercialization
- Buyer aligns timelines to dossier and launch commitments
Key commercial decision points when selecting an imipenem/cilastatin supplier
1) Regulatory file alignment
- Supplier must have DMF/ASMF supported by commercial manufacturing at the relevant site(s)
2) Batch-to-batch impurity consistency
- Beta-lactams require tight impurity control. Buyers screen for:
- related substances ranges
- consistent impurity impurity “delta” in stability
- evidence of process robustness
3) Supply continuity risk
Imipenem/cilastatin has episodic supply constraint risk due to:
- fermentation and chemical intermediate supply variability
- specialized beta-lactam processing capacity limitations
- regulatory inspection-driven site capacity shifts
4) Scale and lead time compatibility
- API tend to have longer lead times than non-beta-lactam APIs
- Buyers favor suppliers with proven multi-plant continuity and documented inventory holding practices
Key takeaways
- Imipenem/cilastatin sourcing is dominated by a small set of manufacturers with beta-lactam capability, cilastatin chemistry support, and DMF/ASMF access.
- Buyers typically procure either separate APIs (imipenem and cilastatin) or a fixed-dose combination API, then use a sterile fill-finish partner if they do not receive finished product.
- Supplier selection should prioritize regulatory file access, impurity profile consistency, GMP site stability, and continuity of supply.
FAQs
1) What is the most common sourcing unit for imipenem/cilastatin?
Most supply chains center on API (bulk drug substance) procurement, with optional integration into finished sterile product depending on the buyer’s licensing and manufacturing model.
2) Do buyers usually source imipenem and cilastatin as separate APIs?
They do when the buyer has formulation and compatibility control internally. Otherwise, they source a co-formulated combination approach via the supplier’s validated process or combination API.
3) What documentation matters most in regulatory qualification?
A buyer typically prioritizes DMF/ASMF access, GMP compliance for the manufacturing site, and CoA with impurity/stability controls.
4) Why is supplier continuity a recurring issue for this drug class?
Imipenem/cilastatin requires specialized beta-lactam processing and controls. Capacity shifts from inspections, intermediate shortages, or process changes can tighten availability.
5) What is the key difference between an API supplier and a finished drug product supplier?
An API supplier provides drug substance quality and regulatory file support; a finished product supplier also provides sterile manufacturing controls, batch release testing, and container closure configuration.
References
[1] U.S. Food and Drug Administration. (FDA). Drug Master File (DMF) database and guidance documents. https://www.fda.gov/drugs/drug-master-files-dmfs
[2] European Medicines Agency. (EMA). Active Substance Master File (ASMF) and regulatory guidance. https://www.ema.europa.eu/
[3] U.S. FDA. (FDA). Current Good Manufacturing Practice (cGMP) for finished pharmaceuticals and related guidance. https://www.fda.gov/
